BDX Earnings Date: Nov 5, 2026 (Estimated) — Becton, Dickinson and Company
NYSE · Healthcare · Medical Instruments & Supplies
Updated
When is BDX's next earnings date?
Becton, Dickinson and Company (BDX) is expected to report Q4 2026 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $4.07 on revenue of $5.11B.
How did BDX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q3 2026), Becton, Dickinson and Company posted EPS of $3.23 versus the $3.14 estimate, a beat of 3.2%. Revenue was $4.98B against a $4.89B estimate. The stock's 1-day post-earnings move was +3.8%.
How much does BDX stock move after earnings?
BDX beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.4% (up or down) in the day after earnings.
About Becton, Dickinson and Company
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q3 2026 | 3.14 | 3.23 | +3.19% | $4.98B | ✅ Beat | +3.75% | +7.57% | +9.94% |
| 2026-05-07 | Q2 2026 | 2.77 | 2.90 | +4.69% | $4.71B | ✅ Beat | +5.87% | -0.40% | +4.42% |
| 2026-02-09 | Q1 2026 | 2.82 | 2.91 | +3.19% | $5.25B | ✅ Beat | -1.25% | +6.57% | -0.07% |
| 2025-11-06 | Q4 2025 | 3.91 | 3.96 | +1.28% | $5.89B | ✅ Beat | +0.56% | +8.92% | +9.96% |
| 2025-08-07 | Q3 2025 | 3.41 | 3.68 | +7.92% | $5.51B | ✅ Beat | +8.85% | +13.66% | +11.58% |
| 2025-05-01 | Q2 2025 | 3.28 | 3.35 | +2.13% | $5.27B | ✅ Beat | -18.13% | -19.29% | -16.66% |
| 2025-02-05 | Q1 2025 | 2.99 | 3.43 | +14.72% | $5.17B | ✅ Beat | -7.28% | -7.84% | -6.33% |
| 2024-11-07 | Q4 2024 | 3.77 | 3.81 | +1.06% | $5.44B | ✅ Beat | -5.40% | -3.68% | -8.35% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY26 · $4.90B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Life Sciences | 51.0% | $2.50B | +92.8% | $1.26B | $1.34B | $1.30B | $1.25B |
| Medical | 49.0% | $2.40B | -8.2% | $2.56B | $2.84B | $2.62B | $2.76B |
By region
Q1 FY26 · $5.25B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 60.1% | $3.16B | +2.6% | $2.89B | $3.12B | $3.08B | $3.11B |
| Non-US | 39.9% | $2.09B | +0.2% | $2.10B | $2.32B | $2.09B | $2.16B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.